Acumen Pharma jumps as Alzheimer's drug well-tolerated in early-stage study

Acumen Pharmaceuticals

17/07/2023 15:41

(Updates)
    ** Shares of Alzheimer's drug developer Acumen
Pharmaceuticals  ABOS.O  up 56.4% at $9.82, hitting over 1-1/2
year high 
    ** Co on Sunday said its drug candidate, ACI193, was
well-tolerated in a first in human early-stage trial testing 62
patients with early Alzheimer's disease
    ** The experimental drug that targets a novel form of the
toxic protein beta-amyloid in the brain passed an early safety
test and will advance to a larger trial, company says
    ** Co adds people who got higher doses of the drug also
showed a reduction in amyloid plaque after 6 to 12 weeks
    ** While no drug-related serious adverse events occurred,
10.4% or 5 treated patients developed a brain swelling condition
known as ARIA-E associated with amyloid-targeting treatments
    ** Another 8.3% developed bleeding in the brain associated
with treatment, known as ARIA-H 
    ** "Low ARIA rates very supportive of improved safety
profile and potential dosing at levels allowing improved
efficacy," says Brokerage BTIG 
    ** Including session's gain, stock up 81.5% YTD 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))